A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)

BackgroundThe approval of eslicarbazepine acetate (ESL) by the Food and Drug Administration (FDA) in 2013 marked an advancement in the treatment of adult patients with partial-onset seizures. However, there still remains a paucity of real-world studies regarding the adverse events (AEs) associated w...

Full description

Saved in:
Bibliographic Details
Main Authors: Huafei Tang (Author), Jing Xu (Author), Xian Zhang (Author), Chunliang Chen (Author), Ge Song (Author), Rui Ma (Author), Jinjing Zhao (Author), Qiang Zhao (Author)
Format: Book
Published: Frontiers Media S.A., 2024-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available